Biosensors for bioengineering Archives - Institute for Bioengineering of Catalonia

September 18, 2023

European funding for the treatment of Type 1 diabetes using 3D bioprinting

IBEC researcher Javier Ramón Azcón has been awarded an “ERC Proof of Concept Grant.” This prestigious funding is granted by the European Research Council to explore the commercial and societal potential of research projects conducted in European institutions. Ramón’s project, Uniink, is centered on the treatment of Type 1 diabetes using cell therapy and 3D bioprinting.

May 4, 2023

IBEC becomes the first research center in Spain to certify its laboratories as sustainable

IBEC’s Core Facilities and nine of its research groups have undergone the “green laboratory” certification process granted by the My Green Lab organization, all awarded with the highest levels of … Read more

November 14, 2022November 14, 2022

Researchers develop a “gym on a chip” that will help to study diabetes and find new drugs to treat the disease

Coinciding with World Diabetes Day, researchers from the Institute for Bioengineering of Catalonia (IBEC) reveal a study that combines muscle and pancreatic cells on a single chip and demonstrates that … Read more

April 26, 2022March 25, 2022

Bioengineering to treat diabetes in the media

Researchers from the Institute for Bioengineering of Catalonia (IBEC) led by ICREA Research Professor Javier Ramón, appear in the media for a recent study in collaboration with IDIBAPS researchers, in which they have developed small spheres capable of responding to variations in the levels glucose and produce insulin in vitro.

April 4, 2022March 17, 2022

Innovative bioengineered spheres might help treating diabetes

Researchers from IBEC, in collaboration with IDIBAPS in Barcelona, have developed nontoxic small spheres able to respond to variations in glucose levels, and producing insulin in vitro. These biomimetic spheroids containing pancreatic β-cells were prepared based on 3D bioprinting. This approach might help in the future improving clinical outcomes of β-cell transplantation strategies for diabetes treatment, as well as for in vitro drug screening platforms.